Zobrazeno 1 - 10
of 313
pro vyhledávání: '"Hiroko Yamashita"'
Autor:
Shin Takahashi, Nobuaki Sato, Kouji Kaneko, Norikazu Masuda, Masaaki Kawai, Hisashi Hirakawa, Tadashi Nomizu, Hiroji Iwata, Ai Ueda, Takashi Ishikawa, Hiroko Bando, Yuka Inoue, Takayuki Ueno, Shinji Ohno, Makoto Kubo, Hideko Yamauchi, Masahiro Okamoto, Eriko Tokunaga, Shunji Kamigaki, Kenjiro Aogi, Hideaki Komatsu, Masahiro Kitada, Yasuaki Uemoto, Tatsuya Toyama, Yutaka Yamamoto, Toshinari Yamashita, Takehiro Yanagawa, Hiroko Yamashita, Yoshiaki Matsumoto, Masakazu Toi, Minoru Miyashita, Takanori Ishida, Fumiyoshi Fujishima, Satoko Sato, Takuhiro Yamaguchi, Fumiaki Takahashi, Chikashi Ishioka
Publikováno v:
Translational Oncology, Vol 48, Iss , Pp 102060- (2024)
The TP53 signature is considered a predictor of neoadjuvant chemotherapy (NAC) response and prognostic factor in breast cancer. The objective of this study was to confirm TP53 signature can predict pathological complete response (pCR) and prognosis i
Externí odkaz:
https://doaj.org/article/74d2b36fc35b41b88125efdc9ac30b6a
Autor:
Kanako Hagio, Kanako C. Hatanaka, Toraji Amano, Yoshihiro Matsuno, Yutaka Hatanaka, Hiroko Yamashita
Publikováno v:
Breast, Vol 60, Iss , Pp 206-213 (2021)
Background: Because a number of years may be required for normal cells to develop into carcinoma, genes involved in tumorigenesis and progression might differ among breast cancers in young women and those in older women. The present study sought to a
Externí odkaz:
https://doaj.org/article/9e974a7c6bb04137a1ebc242de1b9d39
Autor:
Kanako Hagio, Toraji Amano, Hideyuki Hayashi, Takashi Takeshita, Tomohiro Oshino, Junko Kikuchi, Yoshihito Ohhara, Ichiro Yabe, Ichiro Kinoshita, Hiroshi Nishihara, Hiroko Yamashita
Publikováno v:
Scientific Reports, Vol 11, Iss 1, Pp 1-10 (2021)
Abstract Clinical targeted sequencing allows for the selection of patients expected to have a better treatment response, and reveals mechanisms of resistance to molecular targeted therapies based on actionable gene mutations. We underwent comprehensi
Externí odkaz:
https://doaj.org/article/bcd6587139f6496c8776ae366ad162a1
Autor:
Takashi Mitamura, Masayuki Sekine, Masami Arai, Yuka Shibata, Momoko Kato, Shiro Yokoyama, Hiroko Yamashita, Hidemichi Watari, Ichiro Yabe, Hiroyuki Nomura, Takayuki Enomoto, Seigo Nakamura, and the Registration Committee of the Japanese HBOC consortium
Publikováno v:
World Journal of Surgical Oncology, Vol 19, Iss 1, Pp 1-4 (2021)
Abstract Disease sites of female genital tract cancers of BRCA1/2-associated hereditary breast and ovarian cancer (HBOC) are less understood than non-hereditary cancers. We aimed to elucidate the disease site distribution of genital cancers in women
Externí odkaz:
https://doaj.org/article/81af1341835d4301a2816f4467770cf3
Autor:
Songji Zhao, Wenwen Yu, Naoyuki Ukon, Chengbo Tan, Ken-ichi Nishijima, Yoichi Shimizu, Kei Higashikawa, Tohru Shiga, Hiroko Yamashita, Nagara Tamaki, Yuji Kuge
Publikováno v:
EJNMMI Research, Vol 9, Iss 1, Pp 1-10 (2019)
Abstract Background Eribulin, an inhibitor of microtubule dynamics, shows antitumor potency against a variety of solid cancers through its antivascular activity and remodeling of tumor vasculature. 18F-Fluoromisonidazole (18F-FMISO) is the most widel
Externí odkaz:
https://doaj.org/article/b74e7ab1c0f64512b58ee9c9b4135a0b
Autor:
Hiroji Iwata, Takayuki Ueno, Shigehira Saji, Norikazu Masuda, Katsumasa Kuroi, Nobuaki Sato, Hiroyuki Takei, Yutaka Yamamoto, Shinji Ohno, Hiroko Yamashita, Kazufumi Hisamatsu, Kenjiro Aogi, Hironobu Sasano, Masakazu Toi
Publikováno v:
ESMO Open, Vol 4, Iss 1 (2019)
Background Neoadjuvant endocrine therapy (NET) can improve surgical outcomes in postmenopausal patients with hormone receptor-positive breast cancer. The Ki67 labelling index after NET has a better prognostic power than that at baseline. However, it
Externí odkaz:
https://doaj.org/article/222cd3236bd44867a2cd80dbe6cb579c
Autor:
Hiroji Iwata, Takayuki Ueno, Shigehira Saji, Norikazu Masuda, Katsumasa Kuroi, Nobuaki Sato, Hiroyuki Takei, Yutaka Yamamoto, Shinji Ohno, Hiroko Yamashita, Kazufumi Hisamatsu, Kenjiro Aogi, Hironobu Sasano, Masakazu Toi
Publikováno v:
ESMO Open, Vol 4, Iss 1 (2019)
Externí odkaz:
https://doaj.org/article/462cae27d84643e5bbede7e3df895eff
Autor:
Takashi Takeshita, Toshihiko Torigoe, Li Yan, Jing Li Huang, Hiroko Yamashita, Kazuaki Takabe
Publikováno v:
Cancers, Vol 13, Iss 1, p 110 (2020)
The cancer-immunity cycle (CIC) is a series of self-sustaining stepwise events to fight cancer growth by the immune system. We hypothesized that immunofunctional phenotyping that represent the malfunction of the CIC is clinically relevant in breast c
Externí odkaz:
https://doaj.org/article/45de41765b8c4da6a562f6d0b645ed26
Autor:
Susumu Ichiyama, Yoko Funasaka, Hiroko Yamashita, Hideto Tamura, Koiti Inokuchi, Hidehisa Saeki
Publikováno v:
Allergology International, Vol 66, Iss 3, Pp 497-498 (2017)
Externí odkaz:
https://doaj.org/article/c98dc31935d14b2fb7ae814bb3608591
Autor:
Jeff Wang, Fumi Kato, Noriko Oyama-Manabe, Ruijiang Li, Yi Cui, Khin Khin Tha, Hiroko Yamashita, Kohsuke Kudo, Hiroki Shirato
Publikováno v:
PLoS ONE, Vol 10, Iss 11, p e0143308 (2015)
To determine the added discriminative value of detailed quantitative characterization of background parenchymal enhancement in addition to the tumor itself on dynamic contrast-enhanced (DCE) MRI at 3.0 Tesla in identifying "triple-negative" breast ca
Externí odkaz:
https://doaj.org/article/1cb312dd925e44c6b43e4fe59d28ada9